SYDNEY, Australia — Apomorphine may represent a novel therapeutic agent to reduce the burden of cognitive impairment in patients with Parkinson's disease (PD). Preliminary findings from a study from ...

TORONTO, ONTARIO--(Marketwired - May 15, 2013) - Cynapsus Therapeutics Inc. (TSX VENTURE:CTH), a specialty pharmaceutical company developing the only known orally administered (sublingual) formulation ...

Please provide your email address to receive an email when new articles are posted on . Apomorphine sublingual film resulted in greater motor improvement and an increase in responders at earlier time ...

Apomorphine subcutaneous infusion is an effective treatment for Parkinson patients whose motor fluctuations are poorly controlled by conventional therapies. This was shown by the large-scale TOLEDO ...

The Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug Application (NDA) for SPN-830, an apomorphine infusion device for the continuous treatment of motor fluctuations ...

The NDA for SPN-830 is supported by data from an extensive development program that includes the phase 3 TOLEDO study and a supportive open-label study. The New Drug Application (NDA) for SPN-830 ...

Learn everything you need to know about Apomorphine-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, warnings ...

Please provide your email address to receive an email when new articles are posted on . Apomorphine may provide relief for patients with Parkinson’s disease during periods of immobility related to ...

The benefits of the dopamine agonist apomorphine in Parkinson's disease have finally been confirmed in a randomized controlled trial, although the drug has been used in the condition for many years.

The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced Parkinson's disease, Supernus Pharmaceuticals announced on Tuesday. The ...